Tham khảo luận văn - đề án 'báo cáo y học: "tpo, but not soluble-il-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders"', luận văn - báo cáo phục vụ nhu cầu học tập, nghiên cứu và làm việc hiệu quả | Int. J. Med. Sci. 2008 5 87 International Journal of Medical Sciences ISSN 1449-1907 2008 5 2 87-91 Ivyspring International Publisher. All rights reserved Research Paper TPO but not soluble-IL-6 receptor levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders Jan Palmblad1 Magnus Bjorkholm2 Jack Kutti3 Gerd Larfars4 Eva Lofvenberg1 Berit Markevarn5 Mats Merup1 Nils Mauritzson6 Jan Westin6 Jan Samuelsson4 and Gunnar Birgegảrd7 1. Hematology Center Karolinska University Hospital Huddinge Stockholm 2. Hematology Center Karolinska University Hospital Solna Stockholm 3. Dept of Hematology Sahlgrenska University Hospital Goteborg 4. Dept of Medicine Stockholm South Hospital Stockholm 5. Dept of Medicine University Hospital Umeả 6. Dept of Hematology University Hospital Lund Sweden 7. Dept of Medicine University Hospital Uppsala for the Swedish MPD Study Group. Correspondence to Jan Palmblad MD PhD Professor of Medicine Dept. of Medicine Karolinska University Hospital Huddinge S-141 86 Stockholm Sweden. Tel 46 8 5858 2693 fax 46 8 711 7684 e-mail address Received Accepted Published Anagrelide is often used in the treatment of thrombocythemia in myeloproliferative disease MPD but information concerning effects of treatment on cytokines involved in regulation of blood platelet levels is limited. Here we investigated serum levels of thrombopoietin TPO and soluble IL-6 receptor sIL-6R in relation to response to treatment with and plasma concentrations of anagrelide. Samples from 45 patients with thrombo-cythemia due to MPD ET 31 PV 14 being treated with anagrelide for 6 months Were analyzed for TPO sIL-6R and anagrelide levels. The mean baseline platelet count was 983x109 L. A reduction of platelets to 600 in asymptomatic or 400 x 109 L in symptomatic patients was defined as a complete remission CR a reduction with 50 of baseline as partial remission and 50 .
